Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2023 16:01 ET | Source: Annexon Biosciences

Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress

Initial Clinical Data Expected from the Phase 2 ARCHER Trial of ANX007 in Geographic Atrophy in Mid-2023 Initial Clinical Data Anticipated from the Phase 1b Trial of ANX009 in Lupus Nephritis in...
April 11, 2023 06:30 ET | Source: Annexon Biosciences

Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference

BRISBANE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
March 06, 2023 06:30 ET | Source: Annexon Biosciences

Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

Initial Clinical Data from Phase 2 Trial of ANX007 in Patients with Geographic Atrophy On-track for Mid-2023 Oral Small Molecule ANX1502, for Autoimmune Indications, Advances into Multi-Ascending...
February 27, 2023 06:30 ET | Source: Annexon Biosciences

Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference

BRISBANE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical...
February 16, 2023 16:05 ET | Source: Annexon Biosciences

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
January 17, 2023 16:30 ET | Source: Annexon Biosciences

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
January 08, 2023 09:00 ET | Source: Annexon Biosciences

Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises

Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications Well-Capitalized with Operating Runway into 2025 Company to Present...
January 06, 2023 06:30 ET | Source: Annexon Biosciences

Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio

BRISBANE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
January 04, 2023 06:30 ET | Source: Annexon Biosciences

Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
November 17, 2022 16:01 ET | Source: Annexon Biosciences

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...